• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bright Minds Biosciences Inc. - common stock (NQ:DRUG)

77.47 -0.17 (-0.22%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bright Minds Biosciences Inc. - common stock

< Previous 1 2 3 4 5 Next >
News headline image
Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy ↗
May 16, 2026
This San Diego biotech develops targeted therapies for RAS/MAPK-driven cancers, advancing several clinical candidates in oncology. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Neurocrine Biosciences to Acquire Celeno Therapeutics in Rare Disease Deal
April 07, 2026
In a move that signals a significant consolidation within the rare endocrine disease market, Neurocrine Biosciences (NASDAQ: NBIX) announced on April 6, 2026, that it has entered into a definitive... 
Via MarketMinute
News headline image
Bright Minds Biosciences Announces Closing of US$175 Million Public Offering
January 09, 2026
From Bright Minds Biosciences
Via GlobeNewswire
The market is filled with gapping stocks in Wednesday's session. ↗
January 07, 2026
Via Chartmill
Traders are paying attention to the gapping stocks in Tuesday's session. ↗
January 06, 2026
Via Chartmill
News headline image
Why Did DRUG Stock Rocket 51% Today? ↗
January 06, 2026
The Phase 2 BREAKTHROUGH trial met its primary goals, showing strong reductions in seizure frequency while maintaining a favorable safety profile. 
Via Stocktwits
Stay updated with the stocks that are on the move in today's pre-market session. ↗
January 06, 2026
Via Chartmill
News headline image
Why Bright Minds Biosciences Stock Topped the Market on Monday ↗
November 17, 2025
The company isn't wasting any time drafting seasoned professionals to help it develop medication for a rare genetic disorder. 
Via The Motley Fool
News headline image
Large Patient Population Is Key Driver For Bright Minds' Growth ↗
September 08, 2025
BTIG initiates coverage on Bright Minds Biosciences with a Buy rating, citing BMB‑101's potential and key Phase 2 data expected by the end of 2025 
Via Benzinga
News headline image
Epilepsy-Focused Bright Minds Biosciences A High-Risk, High-Reward Play, Analyst Initiates With Over 150% Stock Upside ↗
May 07, 2025
Chardan initiates Bright Minds with a Buy rating, citing over $1 billion sales potential for epilepsy drug BMB-101 despite limited clinical data. 
Via Benzinga
News headline image
Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research
March 04, 2025
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
Bright Minds Biosciences to Participate at Three Healthcare Conferences in March
February 24, 2025
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
Biotechs on the Brink: 2 Stocks With Huge Potential
February 14, 2025
BriaCell Therapeutics and Recursion Pharmaceuticals are two biotech firms that may be poised for success in 2025; risk-tolerant investors might keep an eye out. 
Via MarketBeat
News headline image
This Prudential Financial Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday ↗
January 23, 2025
 
Via Benzinga
News headline image
Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer
January 07, 2025
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting
November 21, 2024
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
Meet the Biotech Stock That Has Generated Nvidia-Like Returns in Less Than a Month ↗
November 13, 2024
The reason for the stock's rapid ascent is a mystery. 
Via The Motley Fool
News headline image
Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement
November 04, 2024
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In October 2024 — Where Do Tesla, Nvidia, Apple, DJT Stock Rank? ↗
November 04, 2024
A look at the most-searched tickers on Benzinga Pro for the month of October. Donald Trump and biotech stocks joined the top 10. 
Via Benzinga
Topics Government
News headline image
What's Going On With Bright Minds Biosciences Stock? ↗
October 21, 2024
Bright Minds Biosciences Inc (NASDAQ:DRUG) shares are trading higher again after soaring last week. The company on Monday announced a new collaboration with brain health-focused AI company Firefly... 
Via Benzinga
Topics Artificial Intelligence
News headline image
Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data
October 21, 2024
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
MarketBeat Week in Review – 10/14 - 10/18
October 19, 2024
Stocks struggled for direction, but the trend before tech earnings is still bullish. Nevertheless, investors should expect volatility ahead of the election. 
Via MarketBeat
Topics Artificial Intelligence Economy
News headline image
Crude Oil Down Over 1%; American Express Shares Fall After Q3 Results ↗
October 18, 2024
 
Via Benzinga
News headline image
What's Going On With Bright Minds Biosciences Stock Friday? ↗
October 18, 2024
Bright Minds Biosciences shares are moving higher on Friday. The company announced a $35 million non-brokered private placement. 
Via Benzinga
News headline image
Dow Falls Over 100 Points; Netflix Posts Upbeat Results ↗
October 18, 2024
 
Via Benzinga
Topics Stocks
News headline image
Firefly Neuroscience And Bright Minds Advance Phase 1 Study With AI-Driven Data Analysis ↗
October 17, 2024
Firefly Neuroscience partners with Bright Minds Biosciences to analyze positive Phase 1 data of BMB-101 using advanced AI technology, setting the stage for Phase 2 trials. 
Via Benzinga
Topics Artificial Intelligence
Bright Minds Biosciences (NASDAQ: DRUG) Soars 1800% Amid Short Squeeze Alongside PRSO, ILLR and NIVF
October 16, 2024
Via AB Newswire
News headline image
Dow Jumps 250 Points; U.S. Bancorp Earnings Top Views ↗
October 16, 2024
 
Via Benzinga
Topics Stocks
News headline image
Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models
October 16, 2024
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
US Stocks Mixed; Abbott Reports Better-Than-Expected Q3 Results ↗
October 16, 2024
 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap